There are multiple reasons why disorders of blood chemistry may develop, including respiratory or renal disease, obesity, and medication. Resulting imbalances include acidosis (pH <7.35), alkalosis (pH >7.45), and high or low levels of key electrolyte ions, including sodium, potassium, calcium, magnesium, chloride, hydrogen phosphate, and hydrogen carbonate (bicarbonate). They may be acute or chronic, may occur with varying degrees of severity, and may not be sufficiently counteracted by the body's regulatory/compensatory mechanisms.
Electrolyte balance is normally regulated by the hypothalamus, kidneys, and various hormones, including antidiuretic hormone (ADH), aldosterone (a mineralocorticoid hormone), and parathyroid hormone (PTH). Acid-base balance is linked to fluid and electrolyte balance, and is normally controlled and maintained by immediate buffer systems via the kidneys and the pulmonary system. Respiratory acidosis and alkalosis are accompanied by compensatory renal bicarbonate retention and loss, respectively; metabolic acidosis and alkalosis are accompanied by compensatory hyperventilation and hypoventilation, respectively. Mixed metabolic disorders can occur (e.g., diabetic ketoacidosis complicated by vomiting), and evaluation depends on clinical history and examination, assessment of anion gap, serum electrolytes, and arterial blood gases. These disorders can be effectively evaluated by a stepwise pathophysiological approach.
Respiratory acidosis occurs when arterial partial pressure levels of carbon dioxide (PCO₂) increase above the normal range of 4.7 to 6.0 kPa (35-45 mmHg), due to inefficient clearance of CO₂. This leads to an accumulation of hydrogen ions, causing the arterial pH to fall below 7.35. It may be acute or chronic, and failure to recognise and treat the underlying cause can lead to respiratory failure and death. Causes of respiratory acidosis include COPD, multilobar pneumonia, foreign body aspiration, drug use (such as sedatives, anaesthetics, alcohol, narcotics), and oxygen therapy in patients with COPD.
Chronic respiratory acidosis is commonly caused by obesity and COPD.
Clinical features of respiratory acidosis include respiratory depression (hypoventilation), obtundation, haemodynamic instability, and respiratory muscle fatigue (accessory muscle use, dyspnoea, tachypnoea).
Respiratory alkalosis is an acid-base disorder characterised by a primary reduction in the arterial partial pressure of CO₂ below the normal range of 4.7 to 6.0 kPa (35-45 mmHg), leading to an increase in pH above 7.45 and a subsequent decrease in bicarbonate from a normal value of 24 mmol/L (24 mEq/L). The decrease in PCO₂ typically occurs as a result of alveolar hyperventilation with an excess of CO₂ excretion compared to production. The aetiologies of respiratory alkalosis are multiple and include pulmonary embolism, sepsis and systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS), pneumonia, and hyperventilation syndrome. Respiratory alkalosis can be acute or chronic in nature.
Metabolic acidosis is indicated by an arterial pH of less than 7.35, a decrease in the plasma bicarbonate level, and/or a marked increase in the anion gap (calculated by subtracting the sum of major measured anions, chloride and bicarbonate, from the major measured cation, sodium). Where the anion gap is normal (6-12 mmol/L [6-12 mEq/L]), gastrointestinal or renal causes are common. This is also referred to as hyperchloraemic or non-anion gap metabolic acidosis. Where the anion gap is increased, causes include diabetic ketoacidosis, alcoholic ketoacidosis, lactic acidosis, kidney disease, or ingestion of methanol, ethanol, ethylene glycol, propylene glycol, 5-oxoproline (e.g., in patients with chronic ingestion of paracetamol), or salicylic acid. With simple metabolic acidosis, the normal adaptive respiratory response will decrease the arterial PCO₂ 1.0 to 1.5 times the decrease in serum hydrogen carbonate (bicarbonate).Acute metabolic acidosis is associated with increased morbidity and mortality because of its depressive effects on cardiovascular function, increased risk of cardiac arrhythmias, stimulation of inflammation, and suppression of the immune response.
Metabolic alkalosis is an elevated arterial pH of above 7.45, and is the consequence of disorders that cause either a loss of hydrogen ions from the body or an increase in plasma bicarbonate from a normal value of 24 mmol/L (24 mEq/L). Causes include gastric secretion loss (e.g., vomiting) and mineralocorticoid excess. Patients may present with tingling, muscle cramps, weakness, cardiac arrhythmias, and/or seizures. Some symptoms may be due to a decrease in circulating calcium, which occurs when the pH is high. Patients may develop serious or fatal arrhythmias and/or seizures without preceding symptoms. Compensatory metabolic alkalosis may be an incidental finding in patients with chronic respiratory acidosis.
Defined as a serum sodium <135 mmol/L (<135 mEq/L); severe hyponatraemia is defined as a serum sodium <120 mmol/L (<120 mEq/L). Hyponatraemia is a common electrolyte disorder and is estimated to occur in 15% of all hospital inpatients.Patients with hyponatraemia have increased morbidity and mortality. With few exceptions, when the serum sodium level is low, plasma osmolality is also low (hypotonic hyponatraemia). While defined by the level of sodium, hypotonic hyponatraemia is, in fact, a disorder of water balance. Hyponatraemia is often iatrogenic and avoidable. Common causes are administration of hypotonic fluids to patients and use of thiazide diuretics (more likely to affect older people). Hyponatraemia may also be a clue to the presence of serious underlying medical disorders. Patients who develop hyponatraemia as a result of head injury, intracranial surgery, subarachnoid haemorrhage, stroke, or brain tumours may have cerebral salt-wasting syndrome or syndrome of inappropriate antidiuretic hormone (SIADH).
Hypernatraemia is defined as a plasma sodium concentration of >145 mmol/L (>145 mEq/L). Hypernatraemia is a state of hyperosmolality, and is primarily a result of water deficit or sodium gain. Normally, persistently high sodium levels trigger antidiuretic hormone (ADH) release, stimulating thirst mechanisms so that hypernatraemia rarely develops. Hospitalised patients often have impaired thirst mechanisms, restricted access to water, and an increased risk of water loss (e.g., due to vomiting or fever). They are also at risk for iatrogenic inadequate fluid replacement. Endocrine abnormalities such as diabetes insipidus and mineralocorticoid excess may also lead to hypernatraemia. Examination should focus on volume status.
Hypokalaemia is a serum potassium level <3.5 mmol/L (<3.5 mEq/L). Clinical manifestations are typically seen only if the serum potassium level is <3.0 mmol/L (<3.0 mEq/L), and include muscle weakness, ECG changes, cardiac arrhythmias, rhabdomyolysis, and renal abnormalities. Hypokalaemia may result from decreased potassium intake, increased potassium entry into cells, increased potassium excretion (e.g., from the gastrointestinal tract, via urine or sweat), dialysis, or plasmapheresis. There are multiple causes of hypokalaemia, including vomiting, severe diarrhoea, laxative and bowel cleansing agent use in bulimia nervosa, chronic alcoholism, anorexia nervosa, renal tubular acidosis, primary aldosteronism, salt-wasting nephropathies, and cystic fibrosis. Some medicines can cause hypokalaemia, including diuretics, insulin treatment for diabetic ketoacidosis or nonketotic hyperglycaemia, beta-adrenergic agonists such as salbutamol or terbutaline, theophylline, chloroquine, laxative abuse or bowel-cleansing agent use, and administration of vitamin B12 or folic acid in megaloblastic anaemia.
Significant hyperkalemia is defined as a serum potassium value >6.0 mmol/L (>6.0 mEq/L). Moderate hyperkalemia is defined as serum potassium values in the 5.0 to 6.0 mmol/L (5.0 to 6.0 mEq/L) range. Hyperkalaemia can be life-threatening and may cause cardiac arrhythmias (ventricular fibrillation) by affecting the cardiac action potential. Hyperkalaemia is often multifactorial in aetiology. It may result from effective depletion of the circulating volume by heart failure combined with ACE inhibitors, or from increased dietary potassium intake combined with chronic renal failure. It is essential to take a thorough history of comorbidities and medicines that might increase cellular potassium release or reduce urinary excretion. Reduced potassium excretion occurs in renal failure, volume depletion, and hypoaldosteronism. Dietary factors (e.g., excess consumption of foods high in potassium) or medicines may quickly lead to hyperkalaemia in patients with comorbidities.
Hypocalcaemia is a state of electrolyte imbalance in which the circulating serum calcium level is low. Hypocalcaemia arises mainly from either insufficient entry of calcium into the circulation or an increased loss of calcium from the circulation. There are multiple causes, including iatrogenic post-surgical hypoparathyroidism (usually transient), vitamin D deficiency, hypomagnesaemia, hyperventilation, hypoparathyroidism, pseudohypoparathyroidism, hyperphosphataemia, hungry bone syndrome (rapid influx of calcium into the bones, causing more prolonged hypocalcaemia following parathyroidectomy), acute pancreatitis, and can be drug-induced. It is also seen in critically ill patients.
Hypocalcaemia varies from a mild asymptomatic biochemical abnormality to a life-threatening disorder. Acute hypocalcaemia can lead to paraesthesia, tetany, and seizures. Physical signs may be observed, including Chvostek's sign (twitching of muscles innervated by the facial nerve).
Symptoms from calcium elevation are typically not found unless the calcium is above 3 mmol/L (12 mg/dL). Severe hypercalcaemia symptoms are more likely when calcium is >3.2 mmol/L (>13 mg/dL). Hypercalcaemia is harmful to the function of excitable membranes leading to skeletal muscle and gastrointestinal smooth muscle fatigue. Effects on cardiac muscle include a shortened QT interval and increased risk of cardiac arrest at very high calcium levels. Neurological sequelae include depression, irritability, and, with high enough levels, coma. High calcium may lead to precipitation in soft tissues such as the kidney where renal function may be severely damaged.
The most common causes of hypercalcaemia are primary hyperparathyroidism and malignancy (e.g., multiple myeloma, leukaemia, lung cancer, and breast cancer). Chronic symptoms are more consistent with hyperparathyroidism, whereas recent onset of symptoms suggests malignancy (the tumour is typically very advanced). Signs and symptoms include renal stones (typical of hyperparathyroidism), lethargy, easy fatigue, depression, irritability, constipation, gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, peptic ulcer disease, pancreatitis), polyuria, polydipsia, confusion, and coma. Hypercalcaemia may be asymptomatic.
Hypomagnesaemia is defined as serum magnesium <0.9 mmol/L (<1.8 mEq/L). Serum magnesium level is a poor indicator of the total magnesium content and availability in the body because only 1% of magnesium is found in the extracellular fluid. There is no simple, rapid, and accurate laboratory test to determine total body magnesium status in humans. Magnesium deficiency can be caused by decreased magnesium intake from the diet, decreased magnesium absorption, or increased renal magnesium excretion (renal magnesium wasting). Causes include malnutrition, isolated dietary magnesium deficiency, drug-induced, alcohol abuse and pancreatitis.
Symptoms are non-specific and include: neuromuscular irritability similar to that produced by hypocalcaemia, manifesting with extensor plantar reflexes, positive Trousseau's and Chvostek's signs, and, in severe cases, tetany; cardiovascular features such as rapid heartbeats and an elevated blood pressure, tachycardia, and/or ventricular arrhythmias; central nervous system symptoms of vertigo, ataxia, depression, and seizure activity.
An endocrine disorder in which autonomous overproduction of parathyroid hormone (PTH) results in calcium metabolism derangement. Single parathyroid adenomas are the most common aetiology (approximately 80% of cases) and familial forms are also well defined. Multiple adenomas and hypertrophy of all 4 glands are less common. Diagnosis occurs through testing for a concurrent elevated serum calcium level and an inappropriately elevated intact serum PTH level. Inherited forms, affecting 10% to 20% of patients, lead to hyperfunctioning parathyroid glands. Importantly, <1% of cases of hyperparathyroidism are caused by parathyroid carcinoma. In 2017, normocalcaemic primary hyperparathyroidism was recognised. It presents with high levels of PTH but with normal serum and ionised calcium levels. Some, but not all, patients will go on to develop primary hyperparathyroidism.
Complications due to primary PTH are uncommon and include osteoporosis and bone fracture due to leaching of calcium from bones, and renal calculi due to elevated serum and urine calcium.
Diabetic ketoacidosis (DKA) is characterised by a biochemical triad of hyperglycaemia, ketonaemia, and metabolic acidosis, with rapid symptom onset. It is an acute metabolic complication of diabetes that is potentially fatal and requires prompt medical attention for successful treatment. DKA may be the first presentation of diabetes.
DKA is usually characterised by plasma glucose >13.9 mmol/L (>250 mg/dL), arterial pH 7.0 to <7.3, and the presence of ketonaemia and/or ketonuria although diagnostic criteria can vary between guidelines; see our topic Diabetic ketoacidosis for full details. Serum sodium, chloride, magnesium, and calcium are usually low; serum anion gap is elevated; and serum potassium, urea, and creatinine are usually elevated. Arterial bicarbonate ranges from <10 mmol/L (<10 mEq/L) in severe DKA to >15 mmol/L (>15 mEq/L) in mild DKA. Venous pH is recommended for monitoring treatment. Rarely, patients present with euglycaemic DKA (EDKA) and have a normal blood glucose level.
Successful treatment includes correction of volume depletion, ketogenesis, hyperglycaemia, electrolyte imbalances, and comorbid precipitating events, with frequent monitoring. Complications of treatment include hypoglycaemia, hypokalaemia, pulmonary oedema, and acute respiratory distress syndrome (ARDS). Cerebral oedema, a rare but potentially rapidly fatal complication, occurs mainly in children. It may be prevented by avoiding overly rapid fluid and electrolyte replacement.
A serious metabolic complication of diabetes characterised by profound hyperglycaemia (glucose >33 mmol/L [>600 mg/dL]), hyperosmolality (effective serum osmolality >320 mmol/kg [>320 mOsm/kg]), and volume depletion in the absence of significant ketoacidosis (pH >7.3 and hydrogen carbonate [bicarbonate] >15 mmol/L [>15 mEq/L]). It is most common in older patients with type 2 diabetes. Contributes to less than 1% of all diabetes-related admissions. However, mortality is high at approximately 15%.
Acute cognitive impairment (lethargy, disorientation, stupor) is common and correlates best with effective serum osmolality. Coma is rare and, if seen, is usually associated with a serum osmolality >340 mOsm/kg (>340 mmol/kg). Treatment includes correction of fluid deficit and electrolyte abnormalities and intravenous insulin.
The term renal tubular acidosis (RTA) refers to a group of renal disorders in which there are defects in the reabsorption of bicarbonate or the excretion of hydrogen ions, or both. The acid retention or bicarbonate loss results in the development of hyperchloraemic metabolic acidosis.
Therefore the RTA syndromes are characterized by a relatively normal GFR and a metabolic acidosis accompanied by hyperchloremia and a normal anion gap. Adult patients with RTA are often asymptomatic but may present with muscular weakness related to associated hypokalaemia, nephrocalcinosis, or recurrent renal stones.
Proximal and classic distal RTA are characterised by hypokalaemia. Hyperkalaemia in distal RTA indicates that aldosterone deficiency or resistance is the cause of the problem. There is minimal or absent urine ammonium in hyperkalaemic distal RTA. Serum sodium is usually normal. RTA is rarely symptomatic. Patients with severe acidaemia can show hyperventilation or Kussmaul's breathing due to respiratory compensation. The urine pH exceeds 5.5 in classic distal RTA, but is lower than 5.0 in patients with untreated proximal RTA. Alkali therapy is the mainstay of treatment in all forms of RTA.
Aldosterone’s primary function is to regulate sodium absorption and potassium excretion in the distal tubule. In primary aldosteronism (PA), aldosterone production exceeds the body's requirements and is relatively autonomous with regard to its normal chronic regulator, the renin-angiotensin II (AII) system. This results in excessive sodium reabsorption via the distal nephron, leading to an increase in the volume of water taken up through the nephron contributing to the development of hypertension and suppression of renin-AII.
Urinary loss of potassium and hydrogen ions, exchanged for sodium at the distal nephron, may result in hypokalaemia and metabolic alkalosis if severe and prolonged, however, most of patients are normokalaemic.
Primary aldosteronism is the most common specifically treatable and potentially curable form of hypertension, accounting for at least 5% of hypertensive patients. Approximately 30% have unilateral forms correctable by unilateral laparoscopic adrenalectomy, and 70% have bilateral forms in which hypertension responds well to aldosterone antagonist medication.
Primary adrenal insufficiency, or Addison's disease, is a disorder that affects the adrenal glands, causing decreased production of adrenocortical hormones (cortisol, aldosterone, and dehydroepiandrosterone). This may be caused by a destructive process directly affecting the adrenal glands or a condition that interferes with hormone synthesis. Approximately 90% of the adrenal cortex needs to be destroyed to produce adrenal insufficiency. Addison's disease may be either acute (adrenal crisis) or insidious. It presents with substantial fatigue and weakness associated with mucocutaneous hyperpigmentation, hypotension and/or postural hypotension, and salt craving. The finding of low sodium and high potassium serum levels is typical. If untreated, it is a potentially life-threatening condition. Adrenocorticotrophic hormone stimulation test is performed to confirm or exclude the diagnosis of Addison's disease.
All patients receive mineralocorticoid and glucocorticoid replacement for life, and are instructed to increase the dose of glucocorticoid during surgery and during any stressful or infectious conditions.
Syndrome of inappropriate antidiuretic hormone (SIADH) is defined as euvolaemic, hypotonic hyponatraemia secondary to impaired free water excretion, usually from excessive antidiuretic hormone(ADH) secretion either from the pituitary or more commonly a non-pituitary source which may include medication or cancer (lung malignancy is the most common).
Antidiuretic hormone (ADH), also known as arginine vasopressin, facilitates free water absorption in the collecting tubule. Inappropriate secretion is characterised by hypotonic hyponatraemia, concentrated urine, and a euvolaemic state. It is primarily identified by abnormal serum sodium levels on laboratory testing, but patients may present with signs of cerebral oedema, including nausea, vomiting, headache, mental status changes, increased somnolence, or coma, and appear euvolaemic.
BMJ Publishing Group
This overview has been compiled using the information in existing sub-topics.
Use of this content is subject to our disclaimer